Financial Performance Highlights

Q2 FY27 Performance:

  • Revenue from operations: ₹56 crores (compared to ₹90 crores in Q2 FY26)
  • Out of Q2 FY26 revenue of ₹90 crores, ₹41 crores was from sales to a major customer
  • Employee costs: ₹14 crores (increased from ₹5 crores in Q2 FY26)
  • Other expenses: ₹11 crores (almost flat year-on-year after excluding one-off expenses)
  • Adjusted operating EBITDA: Negative ₹16 crores for the quarter

Half-Yearly Performance:

  • Revenue: ₹160 crores (compared to ₹178 crores in H1 FY26)
  • Adjusted operating EBITDA: ₹19 crores for half year

One-Time Costs and Exceptional Items

The company reported two sets of one-time items totaling ₹83 crores:

  • Exceptional item of ₹68 crores comprising ₹61 crores from termination of exclusive promotion rights and related inventory purchase arrangements with one large customer
  • One-off expenses of approximately ₹15 crores relating to transition and acquisition-related costs of Minipress XL

Strategic Developments and Business Transition

Distribution Network Build-out:

  • Onboarded more than 20 CFAs creating nationwide network with last mile reach
  • Moved from single customer model to independent company with own distribution network
  • Established direct control of supply chain for the first time

Organization Building:

  • Building dedicated therapy-aligned field force targeting 900 MRs
  • 300 MRs specifically allocated for Minipress XL promotion
  • Recruitment of experienced industry professionals (no freshers)
  • Complete field force expected to be in place by Q4 FY27
  • Moved out of global systems and set up own platforms for accounting, HR, and field reporting

Strategic Transactions Completed:

  • Acquired Minipress XL from Pfizer - market-leading cardiology brand with >50% market share
  • Signed exclusive distribution and promotion agreement for retina portfolio (Accentrix and Pagenax)
  • Portfolio now spans six priority therapies: cardiology, pain management, wellness, transplant, gynecology, neurosciences, plus ophthalmology

Financial Guidance and Outlook

Near-term Priorities for FY27:

1. Stabilize and scale business with seamless execution across operations, supply, and commercial model

2. Complete infrastructure build-out with distribution and corporate infrastructure now in place

3. Significant debt reduction

Revenue Expectations:

  • Stabilized revenue base expected to be approximately ₹600 crores
  • Target to double organic revenue in 5-6 years
  • Q3 FY27 expected to show revenue comprising all products in portfolio
  • Clear stable run rate expected by Q1 FY28

Cost Structure:

  • Q3 FY27 may have additional ₹15-20 crores of one-time costs
  • Q4 FY27 expected to show stabilized cost structure
  • Fully loaded employee and other costs expected to be ₹45-50 crores higher than Q1 base
  • Finance cost guidance: ₹15 crores for Q3, ₹10-15 crores for Q4

Margin Expectations:

  • Operating margins expected to be in line with domestic formulation players of similar size and gross margin
  • Gross margin improvements expected to be visible from Q1 FY28 due to new sourcing efficiencies and product mix changes

New Product Strategy

  • New product introductions expected to begin late Q4 or Q1 FY28
  • Strategy includes brand extensions for lifecycle management and new products for existing specialist teams
  • Focus on maximizing productivity of field force
  • Company plans to be "very acquisitive" going forward with disciplined M&A approach

Debt Management

  • Planning significant debt reduction by March 31, 2027 through rights issue
  • Intent to maintain balance sheet with reasonable debt levels, not highly leveraged

Management Commentary

The transition quarter involved ending the old model and beginning a new one, resulting in one-time costs, revenue correction, and upfront investments in people and systems ahead of revenue. Management emphasized that these are transition effects that do not reflect changes in underlying demand for their brands, which have strong doctor loyalty and market leadership positions.